Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Study Title

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Teva Identifier

C38072-AS-30025 | 2015-000865-29

ClinicalTrials.gov Identifier

NCT02452190

Study Status

Completed

Trial Condition(s)

Asthma

Interventions

Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

12 Years and older

Trial Duration

September 28, 2015 - January 31, 2018

Phase

Phase 3

Study Type

Interventional